Results 81 to 90 of about 1,282,511 (265)

Bullous mastocytosis: a Case Report

Journal of the Egyptian Women’s Dermatologic Society
Mastocytosis is a disorder characterized by abnormal mast cell proliferation. The skin is the most common site of involvement. Extracutaneous involvement occurs in systemic mastocytosis with infiltrations in the gastrointestinal tract, lymph nodes, bone ...
Galal El Enany, Noha Nagui, Hanan Nada, Mona R.E. Abdel-Halim, Iman Sany, Ahmad Nada, Omar El Ghanam, Mona M. Korany   +7 more
doaj   +1 more source

Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report

Case Reports in Medicine, 2010
Mast cell disorders are defined by an abnormal accumulation of tissue mast cells in one or more organ systems. In systemic mastocytosis, at least one extracutaneous organ is involved by definition.
Didem Ozdemir, Selcuk Dagdelen, Tomris Erbas, Kemal Agbaht, Songul Serefhanoglu, Salih Aksu, Sibel Ersoy-Evans   +6 more
doaj   +1 more source

Validation of the German version of Infants and Toddlers Dermatology Quality of Life (InToDermQoL) Questionnaire

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Skin diseases can greatly impair quality of life (QoL) of pediatric patients and their families. The Infants and Toddlers Dermatology Quality of Life questionnaire (InToDermQoL) is the first skin‐generic instrument assessing QoL in children ≤ 4 years, as reported by their caregiver. This study aimed to psychometrically
Juliane Traxler, Neuza da Silva Burger, Matthias Augustin, Hagen Ott, Sanna Hoffmann, Regina Fölster‐Holst, Maria Baumeister, Petra Staubach, Rachel Sommer   +8 more
wiley   +1 more source

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level

Human Vaccines & Immunotherapeutics, 2021
Mastocytosis is a rare group of disorders characterized by abnormal accumulation of mast cells in the skin, bone marrow, and internal organs. In particular, patients with systemic mastocytosis are at an increased risk of frequent and severe episodes of ...
Ali Selcuk, Abdullah Baysan
doaj   +1 more source

Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway [PDF]

, 2018
Mutations in KIT and TET2 are associated with myeloid malignancies. We show that loss of TET2-induced PI3K activation and -increased proliferation is rescued by targeting the p110α/δ subunits of PI3K.
Gerbaulet, A, Janga, SC, Kapur, R, Mali, RS, Paczesny, S, Palam, LR, Ramdas, B, Roers, A, Srivatsan, SN, Takemoto, CM, Tiu, RV, Vanhaesebroeck, B, Visconte, V, Xu, M   +13 more
core   +1 more source

Diagnosing Systemic Mastocytosis: State of the Art

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley   +1 more source

Comprehensive mastocytosis data analysis from a single center

BMC Cancer, 2023
Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors.
Tarık Onur Tiryaki, Sıdıka Gülkan Özkan, Simge Erdem, Aynur Dağlar Aday, İpek Yönal Hindilerden, Aslı Gelincik, Can Baykal, Gülçin Yegen, İbrahim Öner Doğan, Nesimi Büyükbabani, Meliha Nalçacı, Akif Selim Yavuz   +11 more
doaj   +1 more source

Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review

Pediatric Dermatology, EarlyView.
ABSTRACT We report an 11‐month‐old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off‐label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of ...
Janis Chang, Aliyah King, Adam Byrne, Carmen Liy‐Wong   +3 more
wiley   +1 more source

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis

Haematologica, 2020
A high allele burden of the KIT D816V mutation in peripheral blood or bone marrow aspirates indicates multi-lineage hematopoietic involvement and has been associated with an aggressive clinical course of systemic mastocytosis.
Georg Greiner, Michael Gurbisz, Franz Ratzinger, Nadine Witzeneder, Svenja Verena Class, Gregor Eisenwort, Ingrid Simonitsch-Klupp, Harald Esterbauer, Matthias Mayerhofer, Leonhard Müllauer, Wolfgang R. Sperr, Peter Valent, Gregor Hoermann   +12 more
doaj   +1 more source

Precision Medicine in Systemic Mastocytosis

Medicina, 2021
Mastocytosis is a rare hematological neoplasm characterized by the proliferation of abnormal clonal mast cells (MCs) in different cutaneous and extracutaneous organs.
M. Nicolosi, A. Patriarca, A. Andorno, A. Mahmoud, A. Gennari, R. Boldorini, G. Gaidano, E. Crisà   +7 more
semanticscholar   +1 more source